Thiogenesis Therapeutics Corp

Q8M

Company Profile

  • Business description

    Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company’s compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

  • Contact

    4 King Street West
    Suite 401
    TorontoONM5H 1B6
    CAN

    T: +1 647 846-7766

    https://www.thiogenesis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

Stocks News & Analysis

stocks

10 of the cheapest global companies with wide moats

These undervalued stocks of high-quality companies could be attractive investments today.
stocks

Bookworm: Buy and hold inspiration from an unlikely source

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks

3 ASX shares to avoid

These shares have surged in price in the last year but are significantly overvalued according to our analysts. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,082.1068.800.86%
CAC 408,052.3624.080.30%
DAX 4023,031.3944.570.19%
Dow JONES (US)41,488.19674.621.65%
FTSE 1008,655.4323.100.27%
HKSE24,145.57185.590.77%
NASDAQ17,754.09105.640.60%
Nikkei 22537,396.52343.420.93%
NZX 50 Index12,166.14100.11-0.82%
S&P 5005,638.94117.422.13%
S&P/ASX 2007,854.1064.400.83%
SSE Composite Index3,426.136.570.19%

Market Movers